BioCentury | Jul 31, 2020
Distillery Therapeutics

Activating potassium channel KCNJ3 to treat epilepsy

DISEASE CATEGORY: Neurology INDICATION: Epilepsy A thiophenylurea-based activator of the potassium channel KCNJ3 could treat epilepsy. In a mouse model of chemically induced epilepsy, the KCNJ3 activator reduced seizure severity and the duration of tonic...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Neurology

...INDICATION: Depression Rat studies suggest inhibiting KCNJ10 in the lateral habenula could help treat depression. In...
...in normal rats. Also in the model, intracerebral injection of KCNJ10-targeting shRNA or a dominant-negative KCNJ10...
...steps could include identifying and testing KCNJ10 inhibitors that specifically target the lateral habenula. TARGET/MARKER/PATHWAY: Potassium channel Kir4.1 (KCNJ10)...
BioCentury | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

...target in the same brain region -- potassium channel Kir4.1 (KCNJ10) expressed in astrocytes. A proteomic screen showed KCNJ10...
...In a rat model of depression, shRNA knockdown of KCNJ10 or expression of a dominant-negative KCNJ10...
...firing and depression-like behaviors. According to BioCentury's BCIQ database, no companies are developing compounds against KCNJ10...
BioCentury | Aug 25, 2016
Distillery Techniques

Techniques: Rats and dogs treated with potassium channel Kir1.1 (KCNJ1) inhibitor as models of rare genetic disease Bartter syndrome

Disease models TECHNOLOGY: Animal models Rats and dogs treated with a KCNJ1 inhibitor could be used to screen therapies for Bartter syndrome, a genetic disease involving low potassium levels and consequent cardiovascular and renal symptoms....
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: ATP-dependent potassium channel (KATP)

Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest KATP agonists could help prevent AD in patients with Type II diabetes or other forms of hyperglycemia, which increases the risk of AD. In mouse models of...
BioCentury | May 1, 2014
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Potassium channel Kir4.1 (KCNJ10) Mouse studies...
BioCentury | Sep 30, 2013
Clinical News

Lund University endocrine/metabolic data

Researchers at the university and colleagues reported data from a meta-analysis of 3,610 Type II diabetics showing that carriers of the E23K variant of the KCNJ11 gene had significantly increased rates of total mortality (42%...
BioCentury | Sep 26, 2013
Clinical News

Polymorphism linked to CV death in diabetics

Researchers at Lund University reported data from a meta-analysis of 3,610 Type II diabetics showing that carriers of the E23K variant of the potassium channel Kir6.2 (KCNJ11) gene had significantly increased rates of total mortality...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology , the commercialization arm of the country's Medical Research Council , is taking its search...
BioCentury | Jul 26, 2012
Distillery Therapeutics

Indication: Autoimmune disease

...detecting serum antibodies against KCNJ10 could help diagnose MS. Immunoreactive assays of human serum identified anti-KCNJ10...
...assay and conducting prospective studies in a larger population of patients with MS to evaluate anti-KCNJ10...
Items per page:
1 - 10 of 10